The Biosimilars Market is forecast to grow at a CAGR of 16.0%, reaching USD 59.0 billion in 2031 from USD 28.1 billion in 2026.
Biosimilars are defined as licensed and highly similar versions of biological drugs that have already been approved for use by regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics, coupled with the patent expiration of many blockbuster biologic drugs. The estimated patent and exclusivity expiry of a few of the blockbuster biologics is given below. Due to the structural complexity of biosimilar drugs, multi-layered manufacturing, and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.
The market is propelled by increasing corporate investments in biosimilar development.
Europe dominates the global biosimilars market, driven by the presence of leading biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, and Merck. A well-established regulatory framework for biosimilar approvals, a growing number of product approvals, and advanced healthcare infrastructure further fuel market growth in Europe. North America is also expected to experience significant growth during the forecast period, supported by heightened focus on product development and manufacturers' efforts to capitalize on regional growth opportunities.
Market intelligence is delivered through detailed analysis, charts, and graphics, enabling clients to quickly and effectively understand the global biosimilars market.
The Biosimilars Market Report offers a comprehensive analysis of the industry, providing strategic and executive-level insights backed by data-driven forecasts. This regularly updated report empowers decision-makers with actionable intelligence on market trends, emerging opportunities, and competitive dynamics. Biosimilars are defined as biologic products highly similar to licensed biologic drugs, with minor differences in inactive components. The report also examines technological advancements, key government policies, regulatory frameworks, and macroeconomic factors, delivering a holistic market perspective.
Some of the major players covered in this report include Samsung Bioepis, Stada Arzneimittel AG, Sandoz International GmbH (Novartis), Amgen Inc., Apotex Inc., BioCad, Dr. Reddy's Laboratories Ltd., Biocon, Boehringer Ingelheim International GmbH, Pfizer, BioFactura, and AmerisourceBergen Corporation among others.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 28.1 billion |
| Total Market Size in 2031 | USD 59.0 billion |
| Forecast Unit | Billion |
| Growth Rate | 16.0% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Type, Disease, Regions |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|